Stockscreener 앱 받기
1.08
1.82%
-0.02
시간 외 거래:
1.07
-0.01
-0.93%
전일 마감가:
$1.10
열려 있는:
$1.08
하루 거래량:
267.71K
Relative Volume:
1.31
시가총액:
$137.44M
수익:
-
순이익/손실:
$-18.43M
주가수익비율:
-6.932
EPS:
-0.1558
순현금흐름:
$-12.87M
1주 성능:
-6.90%
1개월 성능:
-21.17%
6개월 성능:
-26.03%
1년 성능:
-34.55%
1일 변동 폭
$1.05
$1.12
1주일 범위
$1.04
$1.2101
52주 변동 폭
$1.04
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Compare TLSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.08 | 141.26M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Tiziana Life Sciences Ltd announced that it has received $0.01665 million in funding - marketscreener.com
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Stake wit - GuruFocus
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Shareholding - GuruFocus
Tiziana executive chairman increases stake - Proactive financial news
Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance - TipRanks
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase - Stock Titan
Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy - Stock Titan
[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC FilingForm 6-K - Stock Titan
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York - NTB Kommunikasjon
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference - Proactive financial news
Biotech Tiziana to brief investors on clinical updates at Jefferies event - Stock Titan
Tiziana Life Sciences (TLSA) Slips 2.65% as Stock Tests Key Support ZoneVolume Oscillator - The Legal Advocate
Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings - Stock Titan
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI - Yahoo! Finance Canada
Tiziana Life Sciences completes enrollment in Phase 2a trial for multiple sclerosis drug foralumab - Pluang
Tiziana Life Sciences (TLSA) Completes Patient Enrollment in Cli - GuruFocus
Tiziana completes enrollment for Phase 2 trial in progressive MS study - Proactive financial news
Why Is TLSA Stock Rising Today? - Stocktwits
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial - Yahoo! Finance Canada
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - The Manila Times
Phase 2a MS trial fully enrolled at Tiziana Life Sciences (NASDAQ: TLSA) - Stock Titan
Tiziana Life Sciences (TLSA) Drops 9% as Biotech Sector Volatility WeighsButterfly Setup - The Legal Advocate
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Tiziana Life Sciences (TLSA) Reports Positive Data on Foralumab for Multiple Sclerosis - GuruFocus
Updated Clinical Results for Tiziana Life Sciences (TLSA) Show P - GuruFocus
Tiziana Life Sciences price target boosted on foralumab update - Yahoo! Finance Canada
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
Tiziana reports encouraging Expanded Access data for Foralumab in MS patients - Proactive financial news
Tiziana posts new data for multiple sclerosis drug (TLSA) - Seeking Alpha
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - BioSpace
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS - Yahoo! Finance Canada
Intranasal foralumab shows SPMS safety and fatigue gains at Tiziana (Nasdaq: TLSA) - Stock Titan
About Us - FinancialContent
Tiziana Brain Trial Draws Fresh Nasdaq Index Attention - Kalkine Media
Tiziana Life Sciences (TLSA) Reports Positive Early Results in C - GuruFocus
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab - Investing News Network
Tiziana Life Sciences (TLSA) Reports Positive Early Results in Clinical Trial - GuruFocus
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial - Yahoo News Canada
Tiziana reports brain inflammation reduction in MSA trial patients By Investing.com - Investing.com Nigeria
Tiziana reports brain inflammation reduction in MSA trial patients - Investing.com UK
Tiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal Foralumab - TipRanks
Tiziana Reports Reduced Brain Inflammation In Multiple System Atrophy Patients Treated With Intranasal Foralumab - Mena FN
Brain inflammation falls in Tiziana (Nasdaq: TLSA) MSA PET trial - Stock Titan
TradingKey - TradingKey
TLSA SEC FilingsTiziana Life Sciences Ltd Com 10-K, 10-Q, 8-K Forms - Stock Titan
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):